Overview

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

Status:
Active, not recruiting

Trial end date:
2024-01-30

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Estradiol
Fulvestrant
Hormones